SF3B3调控FXR剪接促进MYC驱动肝细胞癌发生
该研究在小鼠MYC/MCL1驱动HCC模型中揭示胆汁酸升高与FXR剪接失调,鉴定SF3B3为MYC下游靶点并调控FXR剪接;过表达Fxrα2/α4或敲除Sf3b3可抑制肝癌发生,SF3B抑制剂联合FXR激动剂协同抑制HCC细胞增殖。
要点
- MYC驱动HCC小鼠血清和肝脏胆汁酸升高,尤其初级结合型胆汁酸。
- SF3B3是MYC直接下游靶点,调控FXR剪接,过表达Fxrα2/α4或敲除Sf3b3抑制肝癌发生。
- SF3B抑制剂联合FXR激动剂协同抑制HCC细胞增殖,提示可成药弱点。
核心结论
- SF3B3是MYC驱动肝细胞癌发生的关键下游效应因子和FXR剪接的关键调控因子。
- SF3B3和FXR是MYC扩增型HCC中可成药的弱点。
研究设计与样本
- 采用流体动力学注射MYC和MCL1癌基因诱导小鼠HCC模型。
- 运用UPLC-MS/MS分析胆汁酸,qPCR和western blot检测基因表达,RAP-MS鉴定FXR剪接调控因子。
- 通过体内外实验验证SF3B3功能,并分析临床HCC样本。
主要发现
- MYC驱动HCC小鼠血清和肝脏胆汁酸水平升高,尤其初级结合型胆汁酸。
- MYC驱动HCC小鼠肝脏BSEP受抑且FXR剪接失调。
- SF3B3被鉴定为FXR剪接调控因子,且为MYC直接下游靶点。
- 过表达Fxrα2和Fxrα4或敲除Sf3b3显著阻碍MYC驱动的小鼠肝癌发生。
- SF3B抑制剂联合FXR激动剂协同抑制HCC细胞增殖,临床HCC样本中SF3B3与FXRα2相对表达正相关。
临床怎么用
- SF3B3和FXR可作为MYC扩增型HCC的潜在治疗靶点。
- SF3B抑制剂联合FXR激动剂可能为MYC驱动HCC提供协同治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Dysregulation of the MYC oncogene is a major genetic event in hepatocellular carcinoma (HCC). Farnesoid X receptor (FXR), a bile acid (BA) receptor, has emerged as a promising therapeutic target for various liver diseases. Both BA composition and FXR isoforms have been shown to be significantly altered in human HCCs. This study aimed to investigate their potential roles in MYC -driven hepatocarcinogenesis. APPROACH AND RESULTS: HCC was induced in mice by hydrodynamic injection with MYC and MCL1 oncogenes. Ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis revealed elevated BA levels, particularly primary conjugated BAs, in both serum and livers of MYC -driven HCC mice. Real-time quantitative PCR (qPCR) and western blot analyses demonstrated suppression of bile salt export pump (BSEP) and dysregulation of FXR splicing in the livers of these mice. Using RNA antisense purification-coupled with mass spectrometry (RAP-MS), the splicing factor SF3B3 was identified as a regulator of FXR splicing. Both in silico and in vitro studies confirmed that SF3B3 is a direct downstream target of MYC in mice and humans. Functionally, overexpression of Fxrα2 and Fxrα4 or deletion of Sf3b3 significantly impeded MYC -driven hepatocarcinogenesis in mice. Moreover, combination treatment with an SF3B inhibitor and an FXR agonist synergistically suppressed the proliferation of HCC cells. Analysis of clinical HCC samples revealed a positive correlation between SF3B3 and the relative expression of FXRα2. CONCLUSIONS: SF3B3 is a key downstream effector of MYC -driven hepatocarcinogenesis and a critical regulator of FXR splicing. Both SF3B3 and FXR represent druggable vulnerabilities in MYC -amplified HCC.
引用
- Wang X, Luo J, Han L, et al. FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis. Hepatology. 2025. PMID: 40986891. doi:10.1097/HEP.0000000000001523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。